Benefits
Knee comfort during and after physical activity
In a 5-day crossover trial in 40 active adults without arthritis who had knee discomfort after treadmill walking, one 200 mg dose lowered post-exercise knee pain more than placebo within 2 to 4 hours, and after 5 days of 200 mg twice a day pain scores were about half of baseline while placebo scores did not change. The developer funded the trial.
Joint comfort and function scores over 90 days
In a 90-day trial in 157 active adults aged 40 to 60 with knee or lower back discomfort, 200 mg and 400 mg a day raised musculoskeletal health questionnaire scores by about 10 and 14 points, versus 2 on placebo, with differences from day 30, and in the knee and back groups separately. Product was supplied by the developer.
Joint discomfort after repeated sit-to-stand exercise
In the same 90-day trial, discomfort scored right after four sets of sit-to-stand exercise fell by about 34 points on 400 mg and 26 points on 200 mg (on a 100-point scale), versus 8 on placebo. Scores did not differ from placebo at day 7, and fewer people on either dose needed the rescue pain reliever.
Knee and back flexibility
In the 90-day trial, active flexion of the knee or back measured with a goniometer rose by about 4.8 degrees on 400 mg and 3.9 degrees on 200 mg, versus 0.6 on placebo. In a separate 30-day trial in adults with lower back discomfort, 400 mg a day improved a bending flexibility test more than placebo.
Lower back comfort and daily function
In a 30-day trial in 72 adults aged 18 to 60 with nonspecific lower back discomfort, 200 mg twice a day lowered Roland-Morris disability scores (5.5 versus 2.5 points) and pain scores (31 versus 15 points) more than placebo, with gains still present 7 days after stopping. The lead author worked for the developer.
Mechanism of action
Chaste tree leaf activity (animal and lab work)
In rats, a water extract of fresh Vitex negundo leaves reduced paw swelling and pain responses, showed antihistamine activity in rats, and in lab tests inhibited prostaglandin synthesis and showed antioxidant activity. A review lists flavonoids, lignans, terpenoids and steroids among its compounds. None of this was measured in the Muvz trials.
Ginger compounds (proposed)
The trial authors propose that ginger compounds such as 6-gingerol and 6-shogaol act on the TRPV1 pain receptor and on prostaglandin pathways. These ideas come from other research and were not tested in any Muvz trial, and no human study of the blend measured inflammation markers.
Two standardized extracts
The blend is specified to total flavonoids from the chaste tree extract and gingerols from the ginger extract. No published study has compared Muvz with either extract alone, so the contribution of each part is not known.
Clinical trials
Randomized double-blind placebo-controlled crossover trial; each period was 5 days of 200 mg twice a day or placebo, with a washout of about 5 days (reported as 5 plus or minus 2 days), and knee pain was scored after a treadmill test. Primary outcome was time to meaningful pain relief (at least a 40 percent drop in post-exercise pain) after the first dose. Registered as NCT05052112 (sponsor listed as Vedic Lifesciences). Funded by Enovate Biolife, which supplied the product; the lead author worked for Enovate Biolife; no author was listed at OmniActive. (Srivastava et al. 2023, J Pain Res)
40 healthy, physically active adults (inclusion age 20 to 60; actual ages 36 to 56, 30 women and 10 men) with knee pain of at least 60 mm on a 100 mm scale after treadmill walking and little pain at rest; people with any arthritis were excluded; all 40 completed both periods.
Within 4 hours of the first 200 mg dose, 13 of 40 people (32.5 percent) reached meaningful pain relief on Muvz versus none on placebo (p < 0.0001); the pain intensity difference at 4 hours was 23.6 mm versus a 2.5 mm rise on placebo. After 5 days, post-exercise pain fell from 67.5 to 34.2 mm on Muvz while placebo stayed near 67 mm, and 70 percent versus none were responders. The planned exercise-duration outcome could not separate the treatments, because everyone completed all sessions on both. The paper compared the two treatment periods with two-sample tests rather than paired crossover tests. No adverse events were reported. The complete absence of placebo responders is unusual.
Randomized double-blind placebo-controlled parallel trial of 200 mg a day, 400 mg a day (200 mg twice a day) or placebo for 90 days at six orthopedic clinics in Maharashtra, India; primary outcome was the Musculoskeletal Health Questionnaire (MSK-HQ) score. A 7-day placebo run-in removed anyone whose pain improved on placebo before randomization. Registered as NCT05825222 and CTRI/2023/03/051157. No funding statement; Enovate Biolife provided the product, Vedic Lifesciences facilitated the study and is the registry sponsor, and one author worked for Vedic Lifesciences (the same researcher, by ORCID, was listed at Enovate Biolife as lead author of the two earlier trials); the authors declared no conflicts, and no author was listed at OmniActive. (Kalman et al. 2025, Drug Des Devel Ther)
157 physically active adults aged 40 to 60 with knee (87) or lower back (70) discomfort after a sit-to-stand test; people with advanced knee changes on X-ray were excluded; 152 formed the analysis set.
MSK-HQ scores rose by 13.7 points on 400 mg and 10.4 on 200 mg versus 2.0 on placebo at day 90 (p < 0.0001 for each dose), with differences from day 30 and in knee and back subgroups. Discomfort after sit-to-stand fell by 33.7 and 26.4 points versus 8.3 on placebo (p < 0.0001) but did not differ at day 7. Active flexion rose 4.8 and 3.9 degrees versus 0.6 degrees, quality of life scores improved, and 36 and 29 percent versus 13 percent used no rescue acetaminophen. Adverse events (15, 9 and 13) were all judged unrelated to the product.
Randomized double-blind placebo-controlled parallel trial of two capsules a day of E-PR-01 (400 mg a day, as the later 90-day trial paper reports for this study) or placebo for 30 days, with a 7-day follow-up after stopping; outcomes were functional disability (Roland-Morris), bending flexibility, pain, work productivity and sleep. The abstract gives no registry number or funder; ClinicalTrials.gov record NCT04980469 (sponsor Vedic Lifesciences; September 2021 to February 2022; 72 enrolled; 200 mg capsules twice daily for 30 days; Roland-Morris primary with fingertip-to-floor, pain, work productivity and sleep outcomes; sedentary adults whose pain had lasted 7 to 12 weeks) matches the design, so this link is inferred and is not stated in the paper. The lead author worked for Enovate Biolife, the developer; no author was listed at OmniActive. (Srivastava et al. 2024, J Back Musculoskelet Rehabil)
72 adults aged 18 to 60 with nonspecific lower back discomfort, randomized 1:1.
Compared with placebo, Roland-Morris disability scores fell more (5.47 versus 2.48 points), pain scores fell more (31.29 versus 14.55 points) and forward-bending reach distance improved more (5.60 versus 2.38 cm). Work productivity and sleep quality also improved more than placebo, and pain and function scores still differed from placebo 7 days after stopping. No significant adverse events were reported. Only the abstract could be reviewed for this page.
Randomized double-blind placebo-controlled crossover feasibility study in three phases testing eight proprietary extract combinations as single doses in adults with a history of knee pain aggravated by physical stress; primary outcome was time to meaningful pain relief after exertion. The ginger and Vitex negundo combination (ZV-E, 200 mg), which the later 90-day trial paper identifies as E-PR-01, was one arm. Authors were from Enovate Biolife and a US university; the journal page gives no funding statement; not PubMed indexed. (Srivastava et al. 2024, Int J Clin Trials)
17 adults aged 40 to 60 with activity-related pain (selection details in the study description above).
The abstract reports that more than half of people on the ginger and chaste tree combination reached meaningful pain relief, the fastest of the eight combinations, and that a boswellia, ginger and Plantago combination also passed half at 4 hours. Group sizes and between-group statistics are not given in the abstract. This was a screening study used to choose a candidate, not a test of benefit.
Good Laboratory Practice subchronic toxicity study following OECD Test Guideline 408: Muvz at 0, 1000, 2000 or 3000 mg per kg body weight a day by gavage for 90 days, with a 28-day recovery group. Funded by Enovate Biolife; the single author works at Vedic Lifesciences. (Shanmugasundaram 2026, J Toxicol)
Sprague Dawley rats, 10 per sex per group, plus recovery groups of 5 per sex.
No product-related effects on deaths, clinical signs, body weight or food intake were seen, and no product-related tissue lesions were found; some blood test differences were not dose-related and were judged incidental. The no-observed-adverse-effect level was the top dose, 3000 mg per kg a day. This is an animal safety study and does not show any effect in people.